OptiPin
Are peptides legal in the US? The 2026 FDA status
In April 2026 BPC-157, TB-500 and other peptides came off the FDA's Category 2 list. In July an FDA advisory committee voted to recommend six of seven of them for compounding. Neither step makes them legal to compound yet, and neither is an approval. This is a plain explainer of each step and what it does not mean. It is educational, not legal or medical advice.
- • Off Category 2 is not on the list. In April 2026 the FDA moved BPC-157, TB-500 and others to a "nominated but withdrawn" list. That ends their Category 2 status; it does not put them in Category 1 or on the 503A bulks list.
- • The committee said yes to six of seven. On July 23–24, 2026 the PCAC backed BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, each for one named use, and voted against emideltide (DSIP). FDA staff had recommended against all seven.
- • The FDA has not acted yet. The votes are advisory. Adding a peptide takes a proposed rule, public comment and a final rule, and we found no proposed rule as of October 4, 2026.
- • None is approved. Even a final rule would only allow pharmacy compounding for a patient's prescription. Compounded drugs are not FDA-approved.
What "503A", "Category 1" and "Category 2" mean
US drug compounding runs on two federal tracks. 503A covers traditional pharmacies compounding for an individual patient; 503B covers larger outsourcing facilities. Under 503A a bulk drug substance can be used only if it has a USP monograph, is a component of an FDA-approved drug or appears on the FDA's 503A bulks list. Research peptides have no monograph and no approved product, so the bulks list is their only route.
While the FDA evaluates nominated substances, it sorts them under an interim policy. Category 1 substances are under evaluation, and the FDA does not generally act against pharmacies compounding with them in the meantime. Category 2 substances are ones the FDA said raise significant safety concerns; compounding with them is outside that leniency. In 2023 the FDA put roughly 19 peptides, BPC-157 among them, into Category 2, which is why licensed pharmacies stopped supplying them.
April 2026: off Category 2, onto "nominated but withdrawn"
On February 27, 2026 HHS Secretary Robert F. Kennedy Jr. said about 14 of the 19 would move back toward Category 1. The formal step came in April. After the nominators withdrew their nominations, the FDA moved the peptides to a separate heading on its safety-risk page, "Bulk drug substances nominated but withdrawn", which it describes in one sentence: "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators."
As of the page's April 22, 2026 update that list names AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa, emideltide (DSIP), epitalon, GHK-Cu, ipamorelin, KPV, PEG-MGF, melanotan II, MOTS-c, selank, semax, thymosin alpha-1 and TB-500. The same page still lists its safety concerns for each one; for BPC-157 that is a possible risk of immune reactions by some routes and difficulty characterizing the peptide and its impurities.
What the move does and does not mean:
- • It is not approval. Nothing about it reviews whether a peptide is safe or works.
- • It is not permission. As one law firm summarized it, removal from Category 2 "does not, by itself, place these substances on the 503A bulks list or into Category 1".
- • Some peptides stay in Category 2. Ibutamoren (MK-677) and kisspeptin-10 are still listed for 503A; GHRP-2, GHRP-6 and ipamorelin are still listed for 503B outsourcing facilities.
July 23–24, 2026: the PCAC votes
The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven of the peptides, each for the specific uses the FDA evaluated. FDA staff recommended against adding any of them. The committee disagreed on six:
| Peptide | Use the vote covered | Vote (yes–no) | Outcome |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6 (1 abstain) | Recommended |
| KPV | Wound healing and inflammatory conditions | 8–6 (1 abstain) | Recommended |
| TB-500 (thymosin beta-4 fragment) | Wound healing | 8–6 (1 abstain) | Recommended |
| MOTS-c | Obesity and osteoporosis | 7–5 (2 abstain) | Recommended |
| Semax | Cerebral ischemia, migraine and trigeminal neuralgia | 8–5 (1 abstain) | Recommended |
| Epitalon | Insomnia | 7–4 (1 abstain) | Recommended |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia and narcolepsy | 6–7 (1 abstain) | Not recommended |
Two things to keep straight. First, the committee advises; the FDA decides. The FDA can accept or reject each recommendation. Second, a vote covers the use it was taken on. A recommendation for BPC-157 in ulcerative colitis is not a finding that it works for tendon or joint injuries.
What happens next
For any peptide it decides to add, the FDA would publish a proposed rule, take public comments and then publish a final rule. Lawyers following the process estimate that takes many months. We found no proposed rule as of October 4, 2026. In April the FDA also said it would hold a further PCAC meeting before the end of February 2027 for other peptides, including GHK-Cu.
What this means for access right now
At the pharmacy counter, very little has changed. These peptides are still not lawfully compoundable under 503A, so much of the market still runs through research-use-only (RUO) supply. RUO product carries the same uncertainty it always has: concentration, purity and sterility are not verified for human use, and none of these peptides is an approved medicine you can be prescribed as a finished product.
If you are tracking any of these compounds, the practical points are unchanged: assume nothing about concentration without verification, watch the injection site and keep a clean record of what you took and when. That last part is what a tracker is for.
This page summarizes a moving regulatory situation for education; it is not legal or medical advice, and the status can change whenever the FDA acts. Every peptide named here is unapproved. A favorable advisory vote is not a finding that a peptide is safe or effective. Research-use-only supply is not quality-controlled for human use. An injection site that turns red, hot or increasingly painful, or a fever after injecting, needs medical attention the same day; swelling of the face or throat or trouble breathing needs emergency services. Do not start, stop or source anything based on this page; discuss any compound with a licensed clinician and check the FDA's current position before acting.
Keep a clean record of what you run
Regulatory status shifts; your own log shouldn't have gaps. OptiPin tracks every peptide dose, vial and reconstitution on one on-device timeline – the record a clinician can actually read. iOS only, no account.
Download OptiPinFrequently asked questions
Is BPC-157 legal in the US in 2026?
As of October 4, 2026 BPC-157 is still not lawfully compoundable under section 503A. In April 2026 it moved off the FDA's Category 2 list because its nomination was withdrawn, and on July 23, 2026 an FDA advisory committee voted 8 to 6 (1 abstention) to recommend adding it to the 503A bulks list for ulcerative colitis. That vote is advisory: the FDA still has to decide and go through notice-and-comment rulemaking, and we found no proposed rule as of this date. BPC-157 is not an FDA-approved drug and it is not a scheduled controlled substance.
Did the FDA approve BPC-157?
No. Leaving Category 2 is not approval and neither is a favorable advisory vote. Even a final rule adding BPC-157 to the 503A bulks list would only let licensed pharmacies compound it for an individual patient's prescription. Compounded drugs are not FDA-approved, which means the FDA does not verify their safety, effectiveness or quality before they are sold.
What does nominated but withdrawn mean?
It is the FDA's heading for substances that left Category 2 because the people who nominated them withdrew the nomination. The FDA page says: "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators." It does not place them in Category 1 or on the 503A bulks list, so it is neither a ban lifted into permission nor an approval. The same FDA page still carries its safety concerns for each one, such as the risk of immune reactions and peptide impurities.
How did the July 2026 PCAC vote go?
The committee recommended six of seven peptides for the 503A bulks list, each for a specific use: BPC-157 8–6 (ulcerative colitis), KPV 8–6 (wound healing and inflammatory conditions), TB-500 8–6 (wound healing), MOTS-c 7–5 (obesity and osteoporosis), Semax 8–5 (cerebral ischemia, migraine and trigeminal neuralgia) and Epitalon 7–4 (insomnia). Emideltide (DSIP) failed 6–7. FDA staff had recommended against adding all seven. The votes are not binding on the FDA.
Can a pharmacy compound these peptides now?
Not lawfully under 503A yet. A bulk substance qualifies for 503A compounding only if it has a USP monograph, is a component of an FDA-approved drug or is on the 503A bulks list. These peptides meet none of the three until the FDA finalizes a rule. Removal from Category 2 does not, by itself, place them in Category 1 either, so no enforcement discretion applies.
Does this affect semaglutide or tirzepatide?
No. GLP-1 medications are approved drugs governed by their own status and FDA shortage lists, a separate track from this research-peptide compounding review. See the GLP-1 guide for the compounded-GLP-1 access picture.
Sources & further reading
- FDA – Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026): Category 2 entries, the "nominated but withdrawn" list and the safety concerns for each.
- Federal Register 91 FR 20465 (April 16, 2026), docket FDA-2025-N-6895: notice of the July 23–24 PCAC meeting, the uses evaluated for each peptide and the three 503A routes for a bulk substance.
- FDA – July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (meeting materials).
- McDermott – Bulk list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): vote tallies for all seven peptides.
- Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (July 31, 2026): FDA staff recommendation against all seven; votes nonbinding.
- Orrick – FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings (April 16, 2026): what removal does not do and the second meeting before the end of February 2027.
- Buchanan Ingersoll & Rooney – FDA Advisory Committee Voted Yes On Six Peptides. Now What? (Legal 500, August 25, 2026): why the votes do not authorize compounding.
- Chammout M. The Peptide Reclassification Everyone's Talking About. Pharmacy Times (June 2026): the February 27, 2026 announcement.
- FDA – Compounding and the FDA: Questions and Answers: "Compounded drugs are not FDA-approved."
Regulatory status checked October 4, 2026 against the sources above. It changes when the FDA acts; check the FDA's current position before relying on it.
Related
Peptides guide · BPC-157 tracker · TB-500 tracker · BPC-157 science · MOTS-c guide · GLP-1 & compounding